Research Center The University of Texas / Clinical Laboratory Standards Institute / Austin College of Pharmacy The University of Texas Health Science Center San Antonio Pharmacotherapy Rounds May / /
IndustryTerm
per-protocol / chemical degradation / /
MedicalCondition
Esophageal Candidiasis / IC-invasive candidiasis / disease / FLU / then 50mg/day Refractory Invasive Aspergillosis / OF INVASIVE CANDIDIASIS Aasya S. Nasar / FLU ANF / Neutropenia / osteomyelitis / 50mg/day Invasive Candidiasis / common nosocomial bloodstream infections / then 100mg/day Esophageal Candidiasis / invasive candidiasis / FLU CSF / then 50mg/day Esophageal Candidiasis / FLU MCF / endocarditis / then 50mg/day Invasive Candidiasis / severe infections / infection / invasive fungal infections / infections / chemical degradation Invasive Candidiasis / /
A. Organization / Austin College / University of Texas at Austin / CLSI Antifungal Subcommittee / FDA / University of Texas Health Science Center San Antonio Pharmacotherapy Rounds / Clinical Laboratory Standards Institute / /
Person
Aasya S. Nasar / /
Position
Major / /
Product
Eraxis / Hyun Won US2 Portable Audio Device / amphotericin B / Cancidas / Mycamine / fluconazole / /
GIVE ME A BREAK! IMPLICATIONS OF BREAKPOINT CHANGES ON ECHINOCANDIN THERAPY AND THE TREATMENT OF INVASIVE CANDIDIASIS Aasya S. Nasar, Pharm.D. M.Sc. Candidate, Resident in Pharmacotherapy